Plain-English translation of NCT03222076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Liver disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested whether , an immune-boosting medication, worked better alone or combined with another immune drug called in patients with liver cancer before surgery. The study examined how safe these treatments were and how well they helped shrink tumors before the surgical team removed the cancer.
Liver cancer is difficult to treat, and doctors wanted to see if giving immune therapy before surgery could help destroy cancer cells and improve patient outcomes. This medication works by helping the body's own immune system fight cancer, and the trial explored whether combining two different immune therapies might be even more powerful.
Participants received either one or two immune therapy medications by infusion every two weeks for three cycles before surgery. After surgery in week 7, they continued receiving the same medication(s) every 4–6 weeks for up to 2 years. Throughout the trial, patients underwent blood tests, imaging scans, and clinic visits to monitor how well the treatment worked and to watch for side effects.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States